Despite these advancements, most patients with hormone receptor–positive/ERBB2–negative metastatic breast cancer experience disease progression during first-line ET plus CDK4/6i treatment due to the development of acquired tumor resistance. This evidence concerns the gene ERBB2 and neoplasm.